Author Poeschel, Viola
-
2008 | Conference Abstract
Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with Diffuse Large B-cell Lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL)
Schubert, J.; Ziepert, M.; Lengfelder, E.; Mohren, M.; Peter, N.; Reiser, M. & Clemens, M. et al. (2008)
Onkologie, 31
Basel: Karger.
Details WoS
-
2008 | Journal Article
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Pfreundschuh, M.; Schubert, J.; Ziepert, M.; Schmits, R.; Mohren, M.; Lengfelder, E. & Reiser, M. et al. (2008)
The Lancet Oncology, 9(2) pp. 105-116. DOI: https://doi.org/10.1016/S1470-2045(08)70002-0
Details DOI PMID PMC WoS
-
2010 | Conference Abstract
Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (< 61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab-6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group
Pfreundschuh, M.; Kuhnt, E.; Truemper, L. H.; Osterborg, A.; Trneny, M.; Shepherd, L. & Gill, D. S. et al. (2010)
Blood, 116(21) 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL.
Washington: Amer Soc Hematology.
Details WoS
-
2011 | Conference Abstract
7-year follow-up of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Zwick, C.; Ziepert, M.; Zeynalova, S.; Lengfelder, E.; Steinhauer, H.; Clemens, M. & Nickenig, C. et al. (2011)
Onkologie, 34
Basel: Karger.
Details WoS
-
2011 | Conference Abstract
6-year follow-up of the mint study suggests a role for radiotherapy to bulky disease
Held, G.; Kuhnt, E.; Truemper, L. H.; Osterborg, A.; Trneny, M.; Shepherd, L. & Gill, D. S. et al. (2011)
Onkologie, 34
Basel: Karger.
Details WoS
-
2011 | Journal Article
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Pfreundschuh, M.; Kuhnt, E.; Truemper, L. H.; Osterborg, A.; Trneny, M.; Shepherd, L. & Gill, D. S. et al. (2011)
The Lancet Oncology, 12(11) pp. 1013-1022. DOI: https://doi.org/10.1016/S1470-2045(11)70235-2
Details DOI PMID PMC WoS
-
2014 | Journal Article
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
Pfreundschuh, M.; Poeschel, V.; Zeynalova, S.; Haenel, M.; Held, G.; Schmitz, N. & Viardot, A. et al. (2014)
Journal of Clinical Oncology, 32(36) pp. 4127-U354. DOI: https://doi.org/10.1200/JCO.2013.54.6861
Details DOI PMID PMC WoS
-
2014 | Journal Article
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
Murawski, N.; Pfreundschuh, M.; Zeynalova, S.; Poeschel, V.; Haenel, M.; Held, G. & Schmitz, N. et al. (2014)
Annals of Oncology, 25(9) pp. 1800-1806. DOI: https://doi.org/10.1093/annonc/mdu208
Details DOI PMID PMC WoS
-
2015 | Conference Abstract
Liposomal formulation of vincristine allows for doubling the dose compared to conventional vincristine: Results of the first futility analysis of the OPTIMAL > 60 study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Duecker, S.; Poeschel, V.; Wolf, A.; Held, G.; Murawski, N.; Zwick, C. & Haenel, M. et al. (2015)
Oncology Research and Treatment, 38 pp. 197-198.
Basel: Karger.
Details WoS
-
2015 | Journal Article | Research Paper
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma
Reichwagen, A.; Ziepert, M.; Kreuz, M.; Gödtel-Armbrust, U.; Rixecker, T.; Poeschel, V. & Toliat, M. R. et al. (2015)
Pharmacogenomics, 16(4) pp. 361-372. DOI: https://doi.org/10.2217/PGS.14.179
Details DOI PMID PMC WoS
-
2016 | Journal Article
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
Koch, K.; Hoster, E.; Ziepert, M.; Unterhalt, M.; Ott, G.; Rosenwald, A. & Hansmann, M. L. et al. (2016)
Annals of Oncology, 27(7) pp. 1323-1329. DOI: https://doi.org/10.1093/annonc/mdw185
Details DOI PMID PMC WoS
-
2017 | Journal Article
Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.
Murawski, N.; Amam, J.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al. (2017)
Journal of Clinical Oncology, 35(15_suppl) pp. 7539-7539. DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7539
Details DOI
-
2017 | Journal Article
Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.
Pfreundschuh, M.; Christofyllakis, K.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al. (2017)
Journal of Clinical Oncology, 35(15_suppl) pp. 7506-7506. DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7506
Details DOI
-
2018 | Journal Article
A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group
Staiger, A. M.; Altenbuchinger, M.; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Huettl, K. et al. (2018)
Blood, 132(Supplement 1) pp. 343-343. DOI: https://doi.org/10.1182/blood-2018-99-112450
Details DOI
-
2018 | Journal Article
Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.
Pfreundschuh, M.; Murawski, N.; Ziepert, M.; Altmann, B.; Dreyling, M. H.; Borchmann, P. & Luminari, S. et al. (2018)
Journal of Clinical Oncology, 36(15_suppl) pp. 7574-7574. DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.7574
Details DOI
-
2018 | Journal Article
Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA
Poeschel, V.; Held, G.; Ziepert, M.; Altmann, B.; Witzens-Harig, M.; Holte, H. & Thurner, L. et al. (2018)
Blood, 132(Supplement 1) pp. 781-781. DOI: https://doi.org/10.1182/blood-2018-99-112403
Details DOI
-
2019 | Journal Article
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
Poeschel, V.; Held, G.; Ziepert, M.; Witzens-Harig, M.; Holte, H.; Thurner, L. & Borchmann, P. et al. (2019)
The Lancet, 394(10216) pp. 2271-2281. DOI: https://doi.org/10.1016/S0140-6736(19)33008-9
Details DOI
-
2019 | Journal Article
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Staiger, A. M.; Altenbuchinger, M. ; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Hüttl, K. S. et al. (2019)
Leukemia, 34(2) pp. 543-552. DOI: https://doi.org/10.1038/s41375-019-0573-y
Details DOI
-
2020 | Journal Article | Research Paper |
Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
Høhloch, K. ; Ziepert, M.; Trümper, L. ; Buske, C.; Held, G.; Poeschel, V. & Chapuy, B. et al. (2020)
eJHaem, 1(1) pp. 181-187. DOI: https://doi.org/10.1002/jha2.61
Details DOI
-
2022 | Journal Article
KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
Kaddu-Mulindwa, D.; Altmann, B.; Robrecht, S.; Ziepert, M.; Regitz, E.; Tausch, E. & Held, G. et al. (2022)
The Lancet Haematology, 9(2) pp. e133-e142. DOI: https://doi.org/10.1016/S2352-3026(21)00369-0
Details DOI